Design and methods of a postmarketing pharmacoepidemiology study assessing long-term safety of Prolia® (denosumab) for the treatment of postmenopausal osteoporosis‡

PURPOSE: To describe the rationale and methods for a prospective, open-cohort study assessing the long-term safety of Prolia® for treatment of postmenopausal osteoporosis (PMO) in postmarketing settings. METHODS: Data will be derived from United States Medicare, United Healthcare, and Nordic (Denmar...

Descripción completa

Detalles Bibliográficos
Autores principales: Xue, Fei, Ma, Haijun, Stehman-Breen, Catherine, Haller, Christine, Katz, Leonid, Wagman, Rachel B, Critchlow, Cathy W, Denosumab Global Safety Assessment Team
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2013
Materias:
Original Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4230463/
https://www.ncbi.nlm.nih.gov/pubmed/23857864
http://dx.doi.org/10.1002/pds.3477

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4230463/
https://www.ncbi.nlm.nih.gov/pubmed/23857864
http://dx.doi.org/10.1002/pds.3477

Ejemplares similares